Omnicell reported a strong start to 2022 with GAAP and non-GAAP revenues of $319 million. The company's GAAP net income per diluted share was $0.17, while non-GAAP net income per diluted share was $0.83. Omnicell also launched IVX Station, an innovative robotic compounding technology.
Total GAAP revenues for the first quarter of 2022 were $319 million, up 27% from the first quarter of 2021.
GAAP net income for the first quarter of 2022 was $8 million, or $0.17 per diluted share.
Total non-GAAP revenues for the first quarter of 2022 were $319 million, up 27% from the first quarter of 2021.
Non-GAAP net income for the first quarter of 2022 was $38 million, or $0.83 per diluted share.
For the full year 2022, the Company expects total GAAP and non-GAAP revenues to be between $1.385 billion and $1.410 billion. For the second quarter of 2022, the Company expects total GAAP and non-GAAP revenues to be between $337 million and $343 million.
Analyze how earnings announcements historically affect stock price performance